Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In early studies, retatrutide has shown more pronounced weight loss and fat-burning potential compared to what many patients experience on tirzepatide or other dual-agonist medications
The TGA target timeframe for approval is 150 working days, excluding the time required for the sponsor to answer TGA questions
The report found GLP-1 adoption has continued to increase across the United States, rising to 13.1% of US adults in June 2026 from 12% in November 2025
Patients losing weight very quickly face higher risk of gallstone formation
The included studies varied in design, populations, drug regimens, treatment duration, and body-composition methods
US$ 29.14
US$ 27.08
US$ 23.05
US$ 21.91
